Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Organisation › Details

Antag Therapeutics ApS

Antag Therapeutics is a biotech start-up developing peptide-based therapeutics for the treatment of dietary-related metabolic diseases. The company is a spinout from the University of Copenhagen and stems from the research groups of Professors Mette M. Rosenkilde and Jens J. Holst. *

 

Period Start 2014-01-01 splitoff (date ca.)
  Predecessor University of Copenhagen
Products Industry GIP antagonist
  Industry 2 drug development
Persons Person Sparre-Ulrich, Alexander Hovard (Antag Therapeutics 201706 CEO + Co-Founder)
  Person 2 Drejer, Kirsten (Symphogen 2000–201608 Founding CEO since 201609 Executive Director)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 3B Blegdamsvej
  City 2200 Copenhagen N
  Tel +45-21-456537
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Novo Holdings A/S. (6/26/17). "Press Release: Anti-obesity Start-up Antag Therapeutics ApS Raises 2.7 mEUR with Novo Seeds". Copenhagen.
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Antag Therapeutics ApS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px




» top